* Eagle Pharmaceuticals Inc EGRX.OQ EGRX.O is expected
to show
a rise in quarterly revenue when it reports results on March
13.
* The Woodcliff Lake New Jersey-based company is expected
to
report a 51.8% increase in revenue to $64.259 million from
$42.32 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Eagle
Pharmaceuticals Inc
is for earnings of 83 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $39, above its last closing price
of $26.89.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.88 0.91 1.12 Beat 23.5
Jun. 30 2022 3.32 3.36 1.56 Missed -53.6
Mar. 31 2022 3.88 3.88 4.04 Beat 4
Dec. 31 2021 0.96 0.94 0.85 Missed -9.6
Sep. 0.83 0.83 0.56 Missed -32.8
30 2021
Jun. 30 2021 0.75 0.80 0.93 Beat 16.3
Mar. 31 2021 0.74 0.65 0.24 Missed -63.1
Dec. 31 2020 -0.20 -0.17 0.96 Beat 656.5
This summary was machine generated March 3 at 14:53 GMT. All
figures in US dollars unless otherwise stated